Ying Han1,2, Jing Wang3, Meng Jin2, Lin Jia4, Cuihuan Yan5, Yali Wang1. 1. College of Integrated Chinese and Western Medicine, Hebei Medical University, Shijiazhuang, China. 2. Department of Chinese Medicine, The Third Hospital of Hebei Medical University, Shijiazhuang, China. 3. Department of Chinese Medicine Diagnostics, Hebei University of Chinese Medicine, Shijiazhuang, China. 4. Department II of Respiratory, Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang, China. 5. Institute of Integrated Chinese and Western Medicine, Hebei University of Chinese Medicine, Shijiazhuang, China.
Abstract
INTRODUCTION: The current study is aimed at exploring the effect of Shentong Zhuyu Decoction on the proliferation, migration, invasion, and apoptosis of rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) and its underlying molecular mechanism. MATERIALS AND METHODS: The type II collagen-induced arthritis (CIA) model was established. Subsequently, the RA-FLS were isolated from the CIA rat model and identified by immunohistochemistry. The viability, apoptosis, cell cycle, migration, and invasion of RA-FLS were detected by the cell counting kit 8 (CCK-8) assay, flow cytometry, wound-healing assay, and transwell invasion assay, respectively. The levels of MAPK p38, PPARγ, CTGF, Bcl-2, Bax, caspase-3, IL-1β, MMP-3, CDK4, and cyclin D1 were determined by qRT-PCR and western blotting, respectively. RESULTS: After treatment with Shentong Zhuyu Decoction medicated serum, the OD570 value, migrative and invasive abilities, and the secretion of IL-1β, MMP-3 were remarkably decreased in RA-FLS, while the apoptosis rate was increased. Further, results showed that Shentong Zhuyu Decoction inhibited the transition from the G1 phase to S phase. Additionally, Shentong Zhuyu Decoction significantly inhibited the expression of Bcl-2, CDK4, cyclin D1, MAPK p-p38, and CTGF, whereas elevated the levels of Bax, caspase-3, and PPARγ. Importantly, the effects of Shentong Zhuyu Decoction were consistent with the trends of MAPK P38 inhibitor (SB203580) and PPARγ agonist (GW1929). CONCLUSIONS: Shentong Zhuyu Decoction inhibited viability, inflammatory response, migration, invasion, and transition from the G1 phase to S phase and promoted apoptosis of RA-FLS via the MAPK p38/PPARγ/CTGF pathway.
INTRODUCTION: The current study is aimed at exploring the effect of Shentong Zhuyu Decoction on the proliferation, migration, invasion, and apoptosis of rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) and its underlying molecular mechanism. MATERIALS AND METHODS: The type II collagen-induced arthritis (CIA) model was established. Subsequently, the RA-FLS were isolated from the CIA rat model and identified by immunohistochemistry. The viability, apoptosis, cell cycle, migration, and invasion of RA-FLS were detected by the cell counting kit 8 (CCK-8) assay, flow cytometry, wound-healing assay, and transwell invasion assay, respectively. The levels of MAPK p38, PPARγ, CTGF, Bcl-2, Bax, caspase-3, IL-1β, MMP-3, CDK4, and cyclin D1 were determined by qRT-PCR and western blotting, respectively. RESULTS: After treatment with Shentong Zhuyu Decoction medicated serum, the OD570 value, migrative and invasive abilities, and the secretion of IL-1β, MMP-3 were remarkably decreased in RA-FLS, while the apoptosis rate was increased. Further, results showed that Shentong Zhuyu Decoction inhibited the transition from the G1 phase to S phase. Additionally, Shentong Zhuyu Decoction significantly inhibited the expression of Bcl-2, CDK4, cyclin D1, MAPK p-p38, and CTGF, whereas elevated the levels of Bax, caspase-3, and PPARγ. Importantly, the effects of Shentong Zhuyu Decoction were consistent with the trends of MAPK P38 inhibitor (SB203580) and PPARγ agonist (GW1929). CONCLUSIONS: Shentong Zhuyu Decoction inhibited viability, inflammatory response, migration, invasion, and transition from the G1 phase to S phase and promoted apoptosis of RA-FLS via the MAPK p38/PPARγ/CTGF pathway.
Authors: Anca I Catrina; Camilla I Svensson; Vivianne Malmström; Georg Schett; Lars Klareskog Journal: Nat Rev Rheumatol Date: 2016-12-15 Impact factor: 20.543
Authors: Chiara Angiolilli; Aleksander M Grabiec; Bradley S Ferguson; Caroline Ospelt; Beatriz Malvar Fernandez; Inge E van Es; Lisa G M van Baarsen; Steffen Gay; Timothy A McKinsey; Paul P Tak; Dominique L Baeten; Kris A Reedquist Journal: Ann Rheum Dis Date: 2014-12-01 Impact factor: 19.103
Authors: Maria C Lebre; Pedro L Vieira; Man Wai Tang; Saïda Aarrass; Boy Helder; Thomas Newsom-Davis; Paul P Tak; Gavin R Screaton Journal: J Leukoc Biol Date: 2016-10-12 Impact factor: 4.962
Authors: Maria A Lim; Brenton Louie; Daniel Ford; Kyle Heath; Paulyn Cha; Joe Betts-Lacroix; Pek Yee Lum; Timothy L Robertson; Laura Schaevitz Journal: Front Pharmacol Date: 2017-11-14 Impact factor: 5.810